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SUMMARY
What is known and Objective: Pharmacists have been involved
in providing comprehensive interventions to osteoporosis
patients, but pharmaceutical care issues (PCIs) encountered
during such interventions have not been well documented.
Therefore, the aim of this study was to document PCIs
encountered by post-menopausal osteoporotic women pre-
scribed bisphosphonates.
Methods: A randomized controlled study was conducted from
September 2005-February 2009 in the University Malaya Medi-
cal Centre, Malaysia. This main intervention study measured
the effects of pharmaceutical care on medication adherence,
persistence, quality of life, knowledge and patient satisfac-
tion. However, this manuscript is part of the main interven-
tion study and focuses only on the PCIs encountered.
Inclusion criteria: post-menopausal women diagnosed with
osteoporosis (T-score£)2Æ5/low-trauma fracture) and prescribed
weekly alendronate/risedronate. Exclusion criteria: those with
metabolic bone disease and could not communicate in Eng-
lish. The PCIs identified were collected via personal inter-
views or telephone calls, and each participant was followed-
up for a period of 2 years. All PCIs were discussed with and
confirmed by a physician.
Results and Discussion: Of the 198 participants recruited, 64
(32Æ3%) experienced adverse effects because of bisphospho-
nates whereas one participant (0Æ5%) refused to start bis-
phosphonates because of fear of adverse effects. Most adverse
effects [50 (74Æ6%)] were reported during the first 3 months of
therapy with gastrointestinal problems being the main issue
[23 (11Æ6%)]. Of the nine participants (4Æ5%) who discontinued
bisphosphonates, only three agreed to take another medication.
From the 97 PCIs identified, 77 issues could be classified as
drug-related problems [according to the Pharmaceutical Care
Network Europe Classification v6Æ2]. There were 87 causes, 178
interventions and 77 outcomes. The main problem and cause
of the PCIs encountered were adverse drug events (83Æ1% and
74Æ7% respectively), whereas the main intervention provided
was patient counselling (41Æ0%). All problems were solved
(98Æ5%) except for one because of the lack of cooperation of a
patient. After 2 years, 36 participants (20%) were no longer per-
sistent with therapy, 19 (10Æ6%) did not have clinic follow-up
and 53 (26Æ8%) did not have a bone mineral density scan.
What is new and Conclusion: The main PCIs identified were
related to the use of bisphosphonates and its adverse effects.
The study showed that the presence of a clinical pharmacist
has enabled patients to voice their medication-related issues
and to allow appropriate recommendations and actions to be
taken to resolve these issues.
WHAT IS KNOWN AND OBJECTIVE
Osteoporosis is a ‘disease characterized by low bone mass and
micro-architectural deterioration of bone tissue, enhanced bone
fragility and an increase in fracture risk’.1 The loss of bone
occurs ‘silently’ and progressively and often there is no symp-
tom until the first fracture happens.2 As the disease progresses,
symptoms may include back pain, fractures, loss of height, skel-
etal deformity, neck strain, mid-abdominal pain, alterations in
bowel functions and rarely, lung disease.3
Osteoporosis has become a major public health concern
worldwide. Although osteoporosis is more prevalent in women,
it can also affect men.4 This disease can occur at any age, and in
any racial or ethnic group. However, it is more common in
post-menopausal women, especially Asians or Caucasians.5
Because of the enormous medical and economic impact of osteo-
porosis, measures must be taken to increase awareness, detec-
tion, prevention and treatment of this disease.
Pharmacological interventions for the prevention and treat-
ment of osteoporosis include vitamin and mineral supplementa-
tion, bisphosphonates, hormone replacement therapy, selective
oestrogen receptor modulators, calcitonin, teriparatide and
strontium. However, medications are only safe and effective if
used correctly.
Pharmacists are in a strategic position to provide pharmaceu-
tical care, which is defined as the responsible provision of drug
therapy for the purpose of achieving definite outcomes that
improve quality of life (QOL).6 Pharmacists should counsel
patients on how best to take their medications, which is espe-
cially important for bisphosphonates, as they need to be taken
in a specific manner and for at least a year to be effective in
maintaining bone mineral density (BMD) and to protect against
fracture.7 A review of the literature found that pharmacists have
been involved in providing comprehensive interventions on
osteoporosis patients through screening, early detection of oste-
oporosis,8–15 monitoring of drug therapy 8,16 and patient educa-
tion,12,17,18 but such interventions and the pharmaceutical care
issues (PCIs) encountered have not been well documented.
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Therefore, the aim of this study was to document PCIs encoun-
tered by post-menopausal osteoporotic women prescribed bis-
phosphonates. Clinical and health outcomes (such as change in
BMD, falls and fractures) after 2 years were also determined.
METHODS
A randomized controlled trial (RCT) was conducted from Sep-
tember 2005 to February 2009 in the University Malaya Medical
Centre (UMMC), Malaysia. This main intervention study mea-
sured the effects of pharmaceutical care on medication adher-
ence, persistence, QOL, knowledge and patient satisfaction.
Three methods were used to assess medication adherence: direct-
reporting (by asking the participant, ‘How many doses of alendr-
onate/risedronate did you miss since the last time we met?’), pill
count (by counting the number of bisphosphonate tablets left at
each visit) and self-recording (by asking participants to record
the date they took their bisphosphonates).19 These methods were
validated in a preliminary study on 227 post-menopausal osteo-
porotic women prescribed once-weekly bisphosphonates. Medi-
cation adherence was assessed using the self-recording method
as the exact day when the participant took her weekly medica-
tion could be determined. Details on how adherence was mea-
sured have previously been published.19 The provision of
pharmaceutical care improved medication adherence but not
persistence.19 QOL, knowledge and patient satisfaction were also
higher in participants provided with pharmaceutical care.20,21
This manuscript is part of the RCT but focuses only on the PCIs
encountered. Approval from the Medical Ethics Committee of
UMMC was obtained before commencement of the study. All
participants provided informed written consent.
Participants
Inclusion criteria: Post-menopausal women who had just been
diagnosed with osteoporosis (BMD T-score£)2Æ5/low-trauma
fracture), never been on any osteoporosis therapy within the past
6 months and have just been prescribed once-weekly alendronate
(Fosamax, Merck Sharp & Dohme Corp., Pavia, Italy) or risedr-
onate (Actonel, OSG Norwich Pharmaceuticals Inc., North Nor-
wich, NY, USA). Exclusion criteria: Patients with metabolic bone
disease or other medical conditions or treatment likely to affect
bone metabolism, history of chronic renal, hepatic or gastrointes-
tinal (GI) disease or traumatic lumbar compression fracture.
Sample size
Because this manuscript is part of an intervention study, the
sample size used was based on the main outcome measure of
the intervention study, which was medication adherence. To
detect a mean difference of 5% with a pooled standard devia-
tion of 10% between the control and intervention group, with
80% power of detection and a = 0Æ05, a sample size of at least
64 was required in each group.22 Assuming a 20% loss to fol-
low-up,23 the total number of participants required was at least
77 in each arm.
Outcome measure
Outcome measure of this part of the study was PCIs encoun-
tered by osteoporosis patients. Clinical outcomes of participants
such as change in BMD, falls and fractures after 2 years were
also assessed as these have an impact on the long-term manage-
ment of osteoporosis patients.
Procedure
Participants were randomly allocated to the control or interven-
tion group using the random digits table.24 At baseline, demo-
graphic data of participants were collected and bisphosphonate
was started. Osteoporosis medications were dispensed to all par-
ticipants, with an explanation on how to take the medications.
Intervention was provided by the research pharmacist at
months 0, 3, 6 and 12. Intervention participants received a
‘counselling package’ which consisted of an explanation on oste-
oporosis, risk factors, lifestyle modifications, goals of osteoporo-
sis therapy, adverse effects and the importance of medication
adherence. A medication review was also conducted. Control
participants did not receive any additional counselling. How-
ever, at month 12, control participants were provided the same
‘counselling package’. Both control and intervention participants
were then provided with standard pharmacy service for a year
before they were interviewed again concerning their clinical sta-
tus and also any PCI encountered.
The PCIs identified were collected via personal interviews or
telephone calls at months 0, 1, 2, 3, 4, 5, 6, 9, 12 and 24. Personal
interviews were conducted at each intervention visit (months 0,
3, 6 and 12), although participants were contacted by telephone
calls for the other months. Each participant was followed-up for
a period of 2 years. The differences in the number and type of
PCIs encountered between the control and intervention group
were not assessed in the present study as more PCIs may be
reported by intervention participants (because they were in con-
stant contact with the pharmacist and were more likely to dis-
cuss their problems) than the control group. Therefore, PCIs
encountered by both control and intervention participants were
combined in this report. All PCIs were validated with another
physician, and endoscopy was conducted if required. PCIs iden-
tified were then classified according to the Pharmaceutical Care
Network Europe (PCNE) Classification v6.2.25
Instruments used
A pharmaceutical care plan was used to document all the PCIs.
This care plan was developed in the English language as Eng-
lish is understood by most pharmacists practicing in Malaysia.
Statistical analyses
All data were entered into the Statistical Package for Social Sci-
ences (SPSS) version 15 (Chicago, Illinois, USA). Continuous
data were expressed as mean ± standard deviation (SD). Cate-
gorical variables were expressed as absolute (number) and rela-
tive frequencies (percentage).
RESULTS AND DISCUSSION
A total of 198 participants were recruited in this study. Partici-
pants’ demographic data are shown in Table 1.
Pharmaceutical care issues
A total of 97 PCIs were reported (Table 2). The main PCIs
encountered were attributed to the use of bisphosphonates. A
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total of 64 participants (32Æ3%) experienced adverse effects,
which is slightly less than the 47Æ8% reported by another
study,26 whereas one participant (0Æ5%) refused to start taking
bisphosphonates because of fear of adverse effects. Most [50
(74Æ6%)] adverse effects were reported during the first 3 months
of therapy and were mainly because of the ‘first dose effect’,
with GI problems being the main issue [23 (11Æ6%)], followed by
musculoskeletal pain, headache and fever. Five (2Æ5%) partici-
pants were sent for endoscopy and all were confirmed to have
upper GI ulcers. Some adverse effects were so severe that nine
participants (4Æ5%) discontinued their bisphosphonates, which is
similar to other studies.27–30 Of these nine participants, only
three agreed to take another medication for their osteoporosis.
Despite having experienced adverse effects, most participants
persisted with their bisphosphonates after reassurance by the
pharmacist that these effects were transient. Participants who
had GI effects were counselled again as to the correct method of
taking bisphosphonates, whereas participants who experienced
musculoskeletal pain and fever were advised to take paraceta-
mol to relieve these symptoms. Ultimately, after 2–3 weeks of
therapy, these adverse effects eventually disappeared and par-
ticipants were happy to continue their medication. This indi-
cates that pharmacists play an essential role in counselling
patients on the correct method of taking bisphosphonates and
recommending appropriate actions to relieve these symptoms.
Although patients should be warned of common adverse
effects of medications, there is also a distinct risk that such infor-
mation might be misunderstood, leading to unjustifiable fear of
adverse effects. Subsequently, the patient may refuse to take any
medication 31 as observed in one participant. Although the phar-
macist spent additional time to educate the patient about her
health problem and the benefits of therapy, the participant still
refused to start her osteoporosis medication. However, a year
later, she started taking the once-weekly bisphosphonates when
her BMD scan showed further deterioration.
Other PCIs documented were: no effect of drug treatment (2),
effect of drug treatment not optimal (3), unnecessary drug
treatment (7), therapy recommendation (4) and lifestyle changes
(16) (Table 2).
According to the PCNE classification (v6Æ2), therapy recom-
mendations and lifestyle changes were not considered as drug-
related problems (DRPs), and one problem can have more than
one cause, which can lead to more than one intervention, but
only one outcome. Of the 97 PCIs identified, 77 issues were clas-
sified as DRPs, which were associated with 87 causes, 178 inter-
ventions and 77 outcomes (Table 2). The main problem and
cause of the PCIs encountered were adverse drug events (83Æ1%
and 74Æ7%, respectively), whereas the main intervention pro-
vided was patient counselling (41Æ0%). All problems were
solved (98Æ5%) except for one because of the lack of cooperation
of a patient. All the DRPs were discussed with and confirmed
by a physician. Some of the findings could not be classified
appropriately such as ‘the patient’s fear of starting therapy’ and
‘the cause of adverse effects’, hence ‘P4Æ1: Patient dissatisfied
with therapy despite optimal clinical and economic treatment
outcomes’ and ‘C8Æ1: Other cause (adverse effect of drug)’ were
considered as the closest options. Another limitation of the
PCNE v6Æ2 was that therapy recommendations and lifestyle
changes were not considered as DRPs.
Of the 97 PCIs reported, a total of 91 (93Æ8%) recommenda-
tions were provided by the clinical pharmacist and accepted by
the prescriber. Six PCIs were referred directly to the prescriber
for further action. Similarly, in other studies, 89Æ4% 32 and 95Æ9%
33 of pharmacists’ recommendations made to physicians were
accepted. However, one study showed a low acceptance rate
(39%),34 which may be due to the indirect contact between the
pharmacist and the physician.
During the 2-year study period, the participants asked a total
of 324 questions. The most common questions asked were the
side effects of bisphosphonates [69 (34Æ8%) participants], dura-
tion of bisphosphonate therapy [48 (24Æ2%) participants] and
how to take bisphosphonates [43 (21Æ7%) participants]. Partici-
pants in the present study appeared confused about the dura-
tion they had to be on bisphosphonates. Ten (5Æ1%) participants
believed that they had to remain on therapy for only 6 months,
whereas 38 (19Æ2%) participants believed that their osteoporosis
medications had to be taken life-long. This calls for more effec-
tive communication between patients and their healthcare pro-
viders to ensure better understanding of osteoporosis therapy.
Outcomes of participants after two years
Out of 198 participants, 16 (8Æ1%) could not be contacted due to
a change of telephone numbers, and 2 (1Æ0%) passed away
because of reasons unrelated to osteoporosis. Therefore, only
180 participants (90Æ9%) were included in subsequent analyses.
Thirty-six (20%) participants discontinued their bisphosphonates
because of various reasons (Fig. 1). In addition, 19 (10Æ6%) par-
ticipants defaulted clinic follow-ups because of the following
reasons: 5 (2Æ5%) were too busy, 4 (2Æ0%) had too many other
clinic appointments, 4 (2Æ0%) felt that there was no necessity for
follow-up as they were no longer taking any osteoporosis medi-
cations, 2 (1Æ0%) felt that they were feeling better, 2 (1Æ0%) had
Table 1. Demographic data of participants at baseline
Characteristics
No. of participants
(%) (n = 198)
Mean age ± SD (years) [range] 66Æ1 ± 9Æ3 [42–94]
Ethnicity
Malay 31 (15Æ7)
Chinese 114 (57Æ6)
Indian & othersa 53 (26Æ8)
BMI [mean ± SD] 23Æ8 ± 4Æ4
BMI range
<18Æ5 (underweight) 20 (10Æ1)
18Æ5–24Æ9 (normal) 107 (54Æ0)
25Æ0–29Æ9 (overweight) 54 (27Æ3)
‡30 (obese) 17 (8Æ6)
Level of education
No formal education 16 (8Æ1)
Primary education 43 (21Æ7)
Secondary education 82 (41Æ4)
Diploma/tertiary/postgraduate 57 (28Æ8)
Had a previous fall or fracture 101 (51Æ0)
No. of years menopausal [mean ± SD] 17Æ4 ± 9Æ5
Family history of osteoporosis 40 (20Æ2)
SD, Standard deviation.
aOne participant who was classified under ‘others’ was included under the
Indian group.
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no follow-up appointments scheduled, 2 (1Æ0%) could not afford
to buy osteoporosis medications and 1 (0Æ5%) felt that it was
inconvenient to see the doctor as the hospital was too far (one
of the participants provided more than one reason). This is simi-
lar to previous studies which found that overall, 81Æ7% of
appointments were kept after a period of 1 year,35 the median
persistence for weekly alendronate was 3Æ8 years and the risk of
discontinuing or changing therapy increased with age.36 This
emphasizes the importance of continuity of care, especially for
older patients and those who are still experiencing problems
with their treatment.
A repeat BMD scan is usually required after 2 years of oste-
oporosis therapy. However, 53 (26Æ8%) participants did not
have their BMD scan performed because 15 (9Æ1%) did not
want to, 13 (6Æ6%) had no clinic follow-up, 10 (5Æ1%) could not
be contacted and hence the reasons were not known, 10 (5Æ1%)
did not have a BMD scan order written, two (1Æ0%) had
undergone an operation, two (1Æ0%) passed away, whereas one
(0Æ5%) could not afford to pay for the BMD scan. Participants
were also interested to know whether there was any improve-
ment in their BMD scan. A significant improvement in the
lumbar-spine and femoral neck BMD from baseline was
observed after 2 years, indicating the efficacy of bisphospho-
nates therapy. Pharmacists should educate patients on the
importance of having a BMD scan every 2 years as well as
help monitor patients and remind physicians to order a BMD
scan when required.
A total of 33 (18Æ4%) participants reported 36 events that
occurred during the 2 years after the initiation of bisphospho-
nates. The most frequently reported event was a fall (63Æ9%). Of
the 23 participants who had a fall, nine (39Æ1%) had a fracture
with the fall. In addition, 25 (13Æ9%) participants reported that
they were hospitalized. The most common reasons for the hos-
pital admission were infections [seven (3Æ9%)], operation [six
(3Æ3%)], fractures [four (2Æ2%)] and GI problems [four (2Æ2%)]
which included gastric pain, food poisoning and diverticular
disease. The incidence of falls reported by the participants after
2 years (4Æ5%) appeared consistent with that of another study
(3Æ2%) which compared the incidence of fracture with placebo
(6Æ2%).37 This should encourage osteoporosis patients to be more
persistent with their medications.
The main strength of this study is that it describes in detail the
PCIs encountered by post-menopausal osteoporotic women pre-
scribed once-weekly bisphosphonates, which has been validated
by a physician and classified according to the PCNE classification
(v6Æ2). These findings will enable pharmacists to focus on the
common PCIs encountered by osteoporotic patients during their
counselling session.
One of the limitations in this study is that the research phar-
macist was the same pharmacist who provided the intervention.
The researcher could have carried out actions which may have
resulted in higher numbers of PCIs reported, as patients are
more likely to discuss their problems in a clinical intervention
setting. However, it was not possible to determine fracture out-
comes as 2 years were not long enough to evaluate such long-
term outcome. In addition, data were collected from participants
who understand English only and hence may be a more edu-
cated group (shown by 70% with at least secondary education).
Further studies could be conducted with emphasis on pharma-
cists counselling patients on the possible adverse effects of med-
ications, and actions to be taken over a longer period of time to
detect fracture outcomes.
WHAT IS NEW AND CONCLUSION
The main PCIs identified were related to the use of bisphospho-
nates and its adverse effects. The study showed that the
presence of a clinical pharmacist has enabled patients to voice
their medication-related issues and to allow appropriate recom-
mendations and actions to be taken to resolve these issues.
However, further studies on the benefits of having a clinical
pharmacist in the osteoporosis clinic will enable more real clini-
cal practice issues to be determined.
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